日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR(+)/HER2(-) metastatic breast cancer: a prospective, monocentric study

帕博西尼联合内分泌治疗后进展的HR(+)/HER2(-)转移性乳腺癌患者的治疗疗效和活性：一项前瞻性单中心研究

期刊:Drugs in Context
影响因子:2.8
doi:10.7573/dic.2023-7-5
Palumbo, Raffaella; Quaquarini, Erica; Saltalamacchia, Giuseppe; Malovini, Alberto; Lapidari, Pietro; Tagliaferri, Barbara; Mollica, Ludovica; Teragni, Cristina Maria; Barletta, Chiara; Locati, Laura Deborah; Sottotetti, Federico
肿瘤免疫
HER2
肿瘤
乳腺癌
发表日期：2024
文献求助 收藏

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR(+)/HER2(-) breast cancer treated with CDK4/6 inhibitors and endocrine therapy

接受 CDK4/6 抑制剂和内分泌治疗的晚期 HR(+)/HER2(-) 乳腺癌患者的真实世界队列的健康相关生活质量和临床复杂性

期刊:Drugs in Context
影响因子:2.8
doi:10.7573/dic.2023-1-7
Tagliaferri, Barbara; Mollica, Ludovica; Palumbo, Raffella; Leli, Claudia; Malovini, Alberto; Terzaghi, Matteo; Quaquarini, Erica; Teragni, Cristina; Maccarone, Stefano; Premoli, Andrea; Sottotetti, Federico
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2023
文献求助 收藏

Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study

影响接受抗PD-1/PD-L1抗体治疗的晚期非小细胞肺癌（NSCLC）患者预后的临床和生物学变量：一项前瞻性多中心研究

期刊:Journal of Personalized Medicine
影响因子:3
doi:10.3390/jpm12050679
Quaquarini, Erica; Sottotetti, Federico; Agustoni, Francesco; Pozzi, Emma; Malovini, Alberto; Teragni, Cristina Maria; Palumbo, Raffaella; Saltalamacchia, Giuseppe; Tagliaferri, Barbara; Balletti, Emanuela; Rinaldi, Pietro; Canino, Costanza; Pedrazzoli, Paolo; Bernardo, Antonio
肺癌
肿瘤
肿瘤免疫
PD-L1
CLC
细胞生物学
PD-1
发表日期：2022
文献求助 收藏

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors

肿瘤标志物（CEA、CA15.3）变化在接受 CDK4/6 抑制剂治疗的转移性乳腺癌患者中的预后作用

期刊:Drugs in Context
影响因子:2.8
doi:10.7573/dic.2022-1-3
Sottotetti, Federico; Ferraris, Elisa; Tagliaferri, Barbara; Palumbo, Raffaella; Quaquarini, Erica; Teragni, Cristina; Balletti, Emanuela; Leli, Claudia; Premoli, Andrea; Mollica, Ludovica; Puglisi, Silvia; Sardi, Silvia; Malovini, Alberto; Pedrazzoli, Paolo; Bernardo, Antonio
肿瘤免疫
CDK4
肿瘤
乳腺癌
发表日期：2022
文献求助 收藏

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study

帕博西尼联合内分泌治疗激素受体阳性/HER2受体阴性转移性乳腺癌的治疗模式和疗效：一项真实世界多中心意大利研究

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/1758835920987651
Palumbo, Raffaella; Torrisi, Rosalba; Sottotetti, Federico; Presti, Daniele; Rita Gambaro, Anna; Collovà, Elena; Ferzi, Antonella; Agostinetto, Elisa; Maria Teragni, Cristina; Saltalamacchia, Giuseppe; Tagliaferri, Barbara; Balletti, Emanuela; Bernardo, Antonio; Quaquarini, Erica
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2021
文献求助 收藏

Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer

雄激素受体表达在早期ER+/PgR-/HER2-乳腺癌中的作用

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/1758835920958355
Tagliaferri, Barbara; Quaquarini, Erica; Palumbo, Raffaella; Balletti, Emanuela; Presti, Daniele; Malovini, Alberto; Agozzino, Manuela; Teragni, Cristina Maria; Terzoni, Andrea; Bernardo, Antonio; Villani, Laura; Sottotetti, Federico
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2020
文献求助 收藏

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

绝经后激素受体阳性/HER2阴性转移性乳腺癌患者接受500毫克氟维司群治疗的治疗模式和疗效：一项意大利多中心真实世界经验

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/1758835919833864
Palumbo, Raffaella; Sottotetti, Federico; Quaquarini, Erica; Gambaro, Anna; Ferzi, Antonella; Tagliaferri, Barbara; Teragni, Cristina; Licata, Luca; Serra, Francesco; Lapidari, Pietro; Bernardo, Antonio
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2019
文献求助 收藏

Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis

纳武利尤单抗诱发的甲状腺功能障碍：不寻常的临床表现和具有挑战性的诊断

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2018.00813
Iadarola, Carmine; Croce, Laura; Quaquarini, Erica; Teragni, Cristina; Pinto, Sara; Bernardo, Antonio; Fonte, Rodolfo; Marinò, Michele; Rotondi, Mario; Chiovato, Luca
免疫/内分泌
发表日期：2018
文献求助 收藏

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life

纳米白蛋白结合型紫杉醇（nab-紫杉醇）作为HER2阴性、既往接受过紫杉烷类药物治疗的转移性乳腺癌患者的二线化疗：前瞻性评估其疗效、安全性和生活质量

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S79563
Palumbo, Raffaella; Sottotetti, Federico; Trifirò, Giuseppe; Piazza, Elena; Ferzi, Antonella; Gambaro, Anna; Spinapolice, Elena Giulia; Pozzi, Emma; Tagliaferri, Barbara; Teragni, Cristina; Bernardo, Antonio
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2015
文献求助 收藏

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians

哪些转移性乳腺癌患者能从后续治疗中获益？临床医生的最新进展

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/1758834013508197
Palumbo, Raffaella; Sottotetti, Federico; Riccardi, Alberto; Teragni, Cristina; Pozzi, Emma; Quaquarini, Erica; Tagliaferri, Barbara; Bernardo, Antonio
肿瘤
肿瘤免疫
乳腺癌
发表日期：2013
文献求助 收藏